PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (SerendipityPB1)

Minnesota, United States

The purpose of this research is to study the effectiveness and safety of the medication PB in slowing the frequent urination related to tolvaptan as long-term treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), or frequent urination related to inherited nephrogenic diabetes insipidus as an inherited condition or as an acquired condition from prior treatment with lithium.

Eligibility Criteria

  • Ages 18 years and older
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD) diagnosis
  • Participating in the tolvaptan arm
  • Estimated GFR ≥ 30 ml/min
  • Diagnosis of nephrogenic diabetes insipidus (NDI) (congenital, tolvaptan-induced, or lithium-induced).

Additional inclusion/exclusion criteria may apply

Mayo Clinic
Rochester, MN 55905

For additional information please contact:
Kathleen Leistikow 507-266-1316 or Leistikow.Kathleen@mayo.edu